

H2 E1 5. (Amended) The method according to [any one of claims 1 to 4]claim 1 or claim 2, wherein at least one of the at least one proteinaceous substance harvested is encoded by said gene.

7. (Amended) The method according to any one of [the foregoing claims]claims 1, 2 or 6, wherein said at least one adenoviral E1 protein comprises an E1A protein or a functional homologue, fragment and/or derivative thereof.

8. (Amended) The method according to any one of [the foregoing claims]claims 1, 2 or 6, wherein said at least one adenoviral E1 protein comprises an E1B protein or a functional homologue, fragment and/or derivative thereof.

9. (Amended) The method according to [any one of claims 1 through 8]claim 8, wherein said eukaryotic cell produces from about 2 to about 200-fold more recombinant protein and/or proteinaceous substance than conventional mammalian cell lines.

SUB A4 11. (Amended) The method according to any one of claims 1 [to 10], 2 or 6, wherein said proteinaceous substance is a protein that undergoes post-translational and/or peri-translational modifications.

SUB B4 A5 13. (Amended) The method according to any one of claims [1-12]1, 2 or 6, wherein said proteinaceous substance is erythropoietin, or a functional derivative, homologue or fragment thereof.

A6 Cm't 20. (Amended) The recombinant mammalian cell of claim 18 [or claim 19], wherein said at least one adenoviral E1 protein comprises an E1B protein or a functional homologue, fragment and/or derivative thereof.

A6
Cm'd . 21. (Amended) The recombinant mammalian cell of [any one of claims 18 to 20]claim 18, comprising a nucleic acid derived from an adenovirus encoding said at least one adenoviral E1 protein.

A7 23. (Amended) The recombinant mammalian cell of [any one of claims 18-22]claim 18, wherein said recombinant mammalian cell is derived from a primary cell.

24. (Amended) The recombinant mammalian cell of [any one of claims 18 through 23]claim 18, which recombinant mammalian cell is derived from a human cell.

A8 26. (Amended) The recombinant mammalian cell of [any one of claims 18 through 25]claim 25, wherein said cell further comprises a nucleic acid encoding E2A or a functional homologue, fragment and/or derivative thereof.

28. (Amended) The recombinant mammalian cell of [any one of claims 18 through 27]claim 18, wherein said nucleic acid in a functional format for expressing at least one variable domain, encodes a heavy chain, a variable heavy chain, a light chain and/or a variable light chain of an immunoglobulin.

A9
Cm't 29. (Amended) The recombinant mammalian cell of [any one of claims 18 through 28]claim 18, further comprising another nucleic acid in functional format for expressing at least one counterpart of said at least one variable domain.

30. (Amended) The recombinant mammalian cell of [any one of claims 18 through 29]claim 18, wherein said nucleic acid in functional format for expressing at least one variable domain and/or at least one counterpart thereof encodes an ScFv.

31. (Amended) The recombinant mammalian cell of [any one of claims 18 through 30]claim 18, wherein at least one of said variable domains comprises a human or humanized amino acid sequence.

32. (Amended) The recombinant mammalian cell of [any one of claim 18 through 31]claim 18, wherein at least one of said variable domains is encoded by a nucleic acid under the control of an inducible promoter.

33. (Amended) A process for producing at least one variable domain of an immunoglobulin, said process comprising:

culturing a recombinant mammalian cell [of any one of claims 18-32,]immortalized by the presence of at least one adenoviral E1 protein or a functional derivative, homologue and/or fragment thereof, said recombinant mammalian cell comprising a nucleic acid in a functional format for expressing at least one variable domain of an immunoglobulin or a functional derivative, homologue and/or fragment thereof in a suitable medium; and

harvesting said at least one variable domain of an immunoglobulin from said recombinant mammalian cell and/or said medium.

37. (Amended) A variable domain of an immunoglobulin, or a functional part, homologue or derivative thereof, produced by the process of [any one of claims]claim 33 [through 36].

57. (Amended) The method according to any one of claims [1-17, 33, 34, 39-53, 55 or 56]1, 2 or 6, wherein said eukaryotic cell further comprises a sequence encoding E2A or a functional derivative or analogue or fragment thereof in its genome.